Loading
A phase 3 trial of Talquetamab, Pomalidomide, Teclistamab in multiple myeloma, run by Janssen Research & Development, LLC, active and no longer recruiting.
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide is a phase 3 interventional study registered as NCT06208150 by Janssen Research & Development, LLC, with 838 participants enrolled, started 2024-01-22 and due to reach its primary completion in 2026-04-01. Interventions recorded: Talquetamab, Pomalidomide, Teclistamab, Elotuzumab, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Talquetamab, Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone.
Shares Teclistamab, Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib.
Shares Talquetamab, Teclistamab, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone.
Shares Elotuzumab, Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib.
Shares Elotuzumab, Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone.
Shares Talquetamab, Teclistamab, Bortezomib, Johnson & Johnson.
Shares Talquetamab, Teclistamab, Johnson & Johnson, T-cell engagers (bispecific).
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, PROTACs & molecular glues (targeted protein degradation).